The deal size was increased to $165M in common stock from $150M in common stock. Morgan Stanley, Leerink and Cantor Fitzgerald acted as joint book running managers for the offering.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Closing Bell Movers: Dave & Busters down 11% after Q3 miss
- Rocket Pharmaceuticals announces $150M common stock offering
- Rocket Pharmaceuticals Advances Genetic Therapies Pipeline
- Rocket Pharmaceuticals Advances Danon Disease and PKD Studies
- Rocket Pharmaceuticals has not initiated enrollment in Phase 2 RP-L301 study